Events

Learn more about Allegro Ophthalmics at the following events:

Upcoming Events:

2013 Association for Research in Vision and Ophthalmology (ARVO) meeting
May 5-9, 2013: Integrin Peptide Therapy: The First Wet AMD Experience, presented by Peter Kaiser, MD

  • Date/ time of presentation: Monday, May 6 from 3:15-3:30pm
  • Location: Room 618-620 as part of Session 280, “AMD and Drugs”

Past Events:

2012 American Academy of Ophthalmology (AAO) Meeting
November 1013, 2012: Integrin Peptide Therapy: The Latest Human Clinical Update, presented by Barry Kuppermann, MD PhD

  • Date/ time of presentation: Monday, November 12th from 2:24- 2:31PM
  • Location: S406B
October 4-7, 2012: Integrin Peptide Therapy: The First Human Diabetic Macular Edema (DME) Experience in a Phase 1 Trial
  • Date/ time of presentation: Sunday, October 7th from 9:09-9:15AM
  • Location: Grand Ballroom, Mandarin Oriental hotel, Washington, DC
30th Annual American Society of Retina Specialists (ASRS) Meeting
August 25-29, 2012: Integrin Peptide Therapy: The Human Experience in DME, presented by Dr. Hugo Quiroz-Mercado, MD
  • Date/ time of presentation: Monday, August 27th from 9:06-9:14am
  • Location: Aria Resort, Las Vegas

Club Jules Gonin
June 20-12, 2012: Integrin Peptide Therapy: A New Class of Treatment for Vascular Eye Diseases – The First Human Experience in DME, presented by Hugo Quiroz-Mercado, MD

2012Association for Research in Vision and Ophthalmology (ARVO) Meeting
May 6-10, 2012:  Diabetic Retinopathy- Clinical Research II, presented by David Boyer, MD

2012 World Ophthalmology Congress
Sunday, February 19, 2012: Integrin Inhibition as an Antiangiogenic Strategy for the Treatment of Posterior Segment, presented by Baruch Kuppermann, MD, PhD

2011 ISOPT Clinical
December 1-4, 2011: Integrin Inhibition for DME, presented by Baruch Kuppermann, MD, PhD

2011 American Academy of Ophthalmology Conference, Retina Subspecialty Day
Friday, October 21, 2011: Integrin Peptide Therapy As The Next Generation Treatment for Vascular Eye Diseases, presented by Hugo Quiroz-Mercado, MD

The Retina Society Annual Scientific Meeting
Thursday, September 22, 2011: Phase I Human Safety Study of Integrin Antagonist in Diabetic Retinopathy Subjects, presented by Hugo Quiroz-Mercado, MD

 

 

 

 

 

 

Share

Applications

Allegro is initially focused on diseases that occur at the back of the eye. Allegro’s oligopeptide shows promise with a new ...